T. L. Phạm et al., “RESULT OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE THERAPY FOR DISTANT METASTATIC NON-SMALL-CELL LUNG CANCER WITH PD-L1 ≥1%, EGFR(-), ALK(-) AND ROS1(-)”, JPMP175, no. 37, p. 13, Mar. 2024.